Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Hycamtin vials

Return to PJ Online Home Page

The Pharmaceutical Journal Vol 264 No 7102p970
June 24, 2000 Products

Prescription products

Hycamtin vials

Responsibility for sales, marketing and medical inquires for Hycamtin (topotecan hydrochloride) 4mg vials will be transferred from Smithkline Beecham Pharmaceuticals to Merck Pharmaceuticals UK from June 26. The product will continue to be in the livery of Smithkline Beecham. All orders from this date should be sent to Merck Pharmaceuticals UK, Customer Service Centre, Hunter Boulevard, Magna Park, Lutterworth, Leicestershire LE17 4XN (tel 01455 550911, fax 01455 558586).

Citation: The Pharmaceutical Journal URI: 20001988

Rate this article 

Click to rate

  • 1 star out of 5
  • 2 stars out of 5
  • 3 stars out of 5
  • 4 stars out of 5
  • 5 stars out of 5

0 out of 5 stars

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

RPS publications

Pharmaceutical Press is the publishing division of the Royal Pharmaceutical Society, and is a leading provider of authoritative pharmaceutical information used throughout the world.

Visit rpharms.com

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Rate
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.